to-BBB Collaborates With Lundbeck
Lundbeck and to-BBB are entering into a research collaboration to evaluate delivery of antibodies to the brain for Central Nervous System (CNS) diseases. Reportedly, the research could provide
Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Therapeutics for a total deal value of $125m.